These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 8744469)

  • 21. Visual compatibility of argatroban with selected drugs.
    Hartman CA; Baroletti SA; Churchill WW; Patel P
    Am J Health Syst Pharm; 2002 Sep; 59(18):1784-5. PubMed ID: 12298120
    [No Abstract]   [Full Text] [Related]  

  • 22. Physical compatibility of isavuconazonium sulfate with select i.v. drugs during simulated Y-site administration.
    So W; Kim L; Thabit AK; Nicolau DP; Kuti JL
    Am J Health Syst Pharm; 2017 Jan; 74(1):e55-e63. PubMed ID: 28007722
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Physical compatibility of telavancin hydrochloride with select i.v. drugs during simulated Y-site administration.
    Housman ST; Tessier PR; Nicolau DP; Kuti JL
    Am J Health Syst Pharm; 2011 Dec; 68(23):2265-70. PubMed ID: 22095816
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Visual compatibility of abciximab with selected drugs.
    Baroletti S; Hartman C; Churchill W
    Am J Health Syst Pharm; 2002 Mar; 59(5):466-7. PubMed ID: 11887414
    [No Abstract]   [Full Text] [Related]  

  • 25. Physical compatibility and chemical stability of mycophenolate mofetil during simulated Y-site administration with commonly coadministered drugs.
    Cochran BG; Sowinski KM; Fausel C; Overholser BR
    Am J Health Syst Pharm; 2007 Jul; 64(13):1410-4. PubMed ID: 17592007
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Compatibility of enalaprilat with dobutamine, dopamine, heparin, nitroglycerin, potassium chloride and nitroprusside.
    Schaaf LJ; Tremel LC; Wulf BG; Vernon KK
    J Clin Pharm Ther; 1990 Oct; 15(5):371-6. PubMed ID: 1963175
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Compatibility of aztreonam with selected drugs during simulated Y-site administration.
    Trissel LA; Martinez JF
    Am J Health Syst Pharm; 1995 May; 52(10):1086-90. PubMed ID: 7656099
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Compatibility of ondansetron hydrochloride with fluconazole, ceftazidime, aztreonam, and cefazolin sodium under simulated Y-site conditions.
    Bosso JA; Prince RA; Fox JL
    Am J Hosp Pharm; 1994 Feb; 51(3):389-91. PubMed ID: 8160696
    [No Abstract]   [Full Text] [Related]  

  • 29. Visual compatibility of diltiazem injection with various diluents and medications during simulated Y-site injection.
    Gayed AA; Keshary PR; Hinkle RL
    Am J Health Syst Pharm; 1995 Mar; 52(5):516-20. PubMed ID: 7606558
    [No Abstract]   [Full Text] [Related]  

  • 30. Compatibility of drugs administered as Y-site infusion in intensive care units: A systematic review.
    Castells Lao G; Rodríguez Reyes M; Roura Turet J; Prat Dot M; Soy Muner D; López Cabezas C
    Med Intensiva (Engl Ed); 2020 Mar; 44(2):80-87. PubMed ID: 30262380
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Visual compatibility of blinatumomab with selected drugs during simulated Y-site administration.
    Du Repaire T; Vigne P; Guedon A; Fanciullino R; Gauthier-Villano L; Peres PB; Pourroy B
    Am J Health Syst Pharm; 2017 Aug; 74(16):1217-1218. PubMed ID: 28790072
    [No Abstract]   [Full Text] [Related]  

  • 32. Turbidimetric assessment of the compatibility of taxol with selected other drugs during simulated Y-site injection.
    Trissel LA; Bready BB
    Am J Hosp Pharm; 1992 Jul; 49(7):1716-9. PubMed ID: 1352424
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Compatibility of thiotepa (lyophilized) with selected drugs during simulated Y-site administration.
    Trissel LA; Martinez JF
    Am J Health Syst Pharm; 1996 May; 53(9):1041-5. PubMed ID: 8744467
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Stability and compatibility of fluorouracil and mannitol during simulated Y-site administration.
    Woloschuk DM; Wermeling JR; Pruemer JM
    Am J Hosp Pharm; 1991 Oct; 48(10):2158-60. PubMed ID: 1781472
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Physical compatibility of ceftolozane-tazobactam with selected i.v. drugs during simulated Y-site administration.
    Thabit AK; Hamada Y; Nicolau DP
    Am J Health Syst Pharm; 2017 Jan; 74(1):e47-e54. PubMed ID: 28007721
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Compatibility of Norepinephrine Bitartrate with Levofloxacin and Moxifloxacin During Simulated Y-site Administration.
    Mody V; Shah S; Patel J; Thomas MC
    Int J Pharm Compd; 2016; 20(3):236-238. PubMed ID: 28333664
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Stability of ranitidine hydrochloride with ondansetron hydrochloride or fluconazole during simulated Y-site administration.
    Pompilio FM; Fox JL; Inagaki K; Burm JP; Jhee S; Gill MA
    Am J Hosp Pharm; 1994 Feb; 51(3):391-4. PubMed ID: 8160697
    [No Abstract]   [Full Text] [Related]  

  • 38. Physical compatibility of tedizolid phosphate with selected i.v. drugs during simulated Y-site administration.
    Ghazi I; Hamada Y; Nicolau DP
    Am J Health Syst Pharm; 2016 Nov; 73(21):1769-1776. PubMed ID: 27769972
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Physical compatibility and chemical stability of amikacin sulfate in combination with non-antibiotic drugs in large-volume parenteral solutions - part IV.
    Nunning BC; Granatek AP
    Curr Ther Res Clin Exp; 1976 Oct; 20(4):417-91. PubMed ID: 12918
    [No Abstract]   [Full Text] [Related]  

  • 40. Visual compatibility of enalaprilat with commonly used critical care medications during simulated Y-site injection.
    Halpern NA; Colucci RD; Alicea M; Greenstein R
    Int J Clin Pharmacol Ther Toxicol; 1989 Jun; 27(6):294-7. PubMed ID: 2544533
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.